New drug cocktail shows promise for Hard-to-Treat cancers
NCT ID NCT06394414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called YL201 combined with an immunotherapy (serplulimab) and sometimes chemotherapy in people with advanced solid tumors. The study has two parts: first, finding the safest dose, and then seeing if the combination shrinks tumors. About 187 participants with cancers like lung or nasopharyngeal cancer are enrolled in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YL201 (a drug) combined with serplulimab (an immunotherapy) and optionally platinum-based chemotherapy
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors like lung or nasopharyngeal cancer.
What could go wrong
This is an early Phase 1 trial, so it is primarily testing safety and dosing. It is too soon to know if the combination will work, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
-
Cancer Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijinig, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
-
Liaoning Provincial Cancer Hospital
Shenyang, Liaoning, China
-
Linyi Central Hospital
Linyi, Shandong, China
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, China
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
-
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Hospital of Jilin University
Changhua, Jilin, China
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
Union Hospital Tongji Medical College HuaZhong University of Science Technology
Wuhan, Hubei, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
West China Hospital, Sichuan University
Sichuan, Sichuan, China
-
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, China
-
Zhejiang Provincial Cancer Hospital
Hangzhou, Zhejiang, China